Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions - PubMed
2 days ago
- #Inflammatory Disorders
- #Anti-TL1A Therapy
- #Tulisokibart
- Tulisokibart and anti-TL1A therapy show promise for treating inflammatory disorders like inflammatory bowel disease.
- The therapy targets the TL1A-DR3 pathway, which is involved in inflammation and fibrosis.
- Research indicates these treatments may reduce gut pathobionts and modulate autoimmune responses.
- Future directions focus on expanding applications in autoimmune conditions and refining therapeutic strategies.